Pyrazinamide News and Research

RSS

Researchers tackling deadly TB discuss the way forward in treatment and prevention

Researchers from across the world who are tacking the deadly bacterial disease tuberculosis (TB) attended a symposium at St George's, University of London to discuss the way forward in treatment and prevention.

29 Nov 2017

UCLA-led researchers identify potential TB drug regimen that may cut treatment time up to 75%

Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.

25 Jan 2017

Cochrane review explores FDCs versus single-drug formulations for treatment of pulmonary TB

A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB).

23 May 2016

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study -- a 10-nation, randomized clinical trial of adult outpatients -- investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS.

18 Mar 2016

Treating multidrug-resistant tuberculosis with regimens may improve outcomes

Treating multidrug-resistant tuberculosis (MDR TB) with regimens that include a greater number of drugs may improve outcomes, and baseline drug susceptibility testing (DST) could identify drugs with the greatest likelihood of success, according to a paper published this week in PLOS Medicine.

30 Dec 2015

TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB), has received a grant from the Australian Department of Foreign Affairs and Trade to support late-stage clinical trials of new TB treatments.

25 Mar 2015

PaMZ drug regimen shows potential to improve treatment for MDR-TB

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.

19 Mar 2015

Eating food just before taking TB drug could reduce effectiveness of medicine

The timing of food intake in the early phase of TB treatment could have a negative impact on the effectiveness of TB treatment.

8 Sep 2014

Researchers discover new clue to understanding how TB medication attacks dormant TB bacteria

Researchers at the Johns Hopkins Bloomberg School of Public Health say they have discovered a new clue to understanding how the most important medication for tuberculosis (TB) works to attack dormant TB bacteria in order to shorten treatment.

13 Aug 2014

TB Alliance advances first-ever TB drug regimen to global Phase 3 clinical trial

Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase 3 clinical trial.

25 Apr 2014

EPFL sets up foundation to release antibiotic for tuberculosis

Even though tuberculosis kills more than 1.5 million people every year, the market is not cost-effective for pharmaceutical companies. So EPFL is setting up a foundation to release an antibiotic developed in its own laboratories under EU funding.

12 Mar 2014

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

In an effort to develop and deliver treatments for children with tuberculosis—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments.

30 Oct 2013

BP and headache drug effectively speeds up treatment of TB

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

30 Aug 2013

Study provides new insight into how pyrazinamide works

Pyrazinamide (PZA)-a frontline tuberculosis drug-kills dormant persister bacteria and plays a critical role in shortening TB therapy. PZA is used for treating both drug susceptible and multi-drug resistant TB but resistance to PZA occurs frequently and can compromise treatment.

14 Jun 2013

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

TB Alliance and FIND partner to promote development of TB drugs and diagnostics

A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

19 Oct 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

Novel combination drug regimen could be more effective than existing treatments for TB

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet.

24 Jul 2012

TB combination drug trials progress

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.